Pulse Biosciences (NASDAQ:PLSE) Sets New 12-Month High – Here’s What Happened

Pulse Biosciences, Inc (NASDAQ:PLSE)’s share price hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $28.98 and last traded at $29.6750, with a volume of 60412 shares changing hands. The stock had previously closed at $27.50.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Canaccord Genuity Group assumed coverage on Pulse Biosciences in a research note on Thursday, June 4th. They issued a “buy” rating and a $32.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $30.67.

Pulse Biosciences Price Performance

The stock has a market capitalization of $1.99 billion, a P/E ratio of -26.05 and a beta of 1.65. The stock’s fifty day moving average is $24.07 and its 200-day moving average is $20.04.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Monday, May 4th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.05. The company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.25 million. On average, research analysts expect that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Insider Transactions at Pulse Biosciences

In related news, Director Robert W. Duggan bought 660,233 shares of Pulse Biosciences stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $19.69 per share, for a total transaction of $12,999,987.77. Following the acquisition, the director owned 48,211,433 shares in the company, valued at $949,283,115.77. This trade represents a 1.39% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Paul A. Laviolette bought 15,000 shares of Pulse Biosciences stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $19.69 per share, with a total value of $295,350.00. Following the completion of the acquisition, the chief executive officer owned 15,000 shares in the company, valued at approximately $295,350. The trade was a ? increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 74.00% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

A number of institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its stake in shares of Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after buying an additional 619 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after buying an additional 680 shares during the period. Alliancebernstein L.P. grew its stake in Pulse Biosciences by 6.7% in the 3rd quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock valued at $365,000 after buying an additional 1,300 shares during the last quarter. Westside Investment Management Inc. grew its stake in Pulse Biosciences by 2.9% in the 4th quarter. Westside Investment Management Inc. now owns 66,326 shares of the company’s stock valued at $911,000 after buying an additional 1,886 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after acquiring an additional 2,156 shares during the period. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.